Is the Combination of Piperacillin-Tazobactam and Vancomycin Associated with Development of Acute Kidney Injury? A Meta-analysis

Pharmacotherapy

Volumn 36, Issue 12, 2016, Pages 1217-1228

  Giuliano, Christopher A ^a   Patel, Chandni R ^a   Kale Pradhan, Pramodini B ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

acute kidney injury; nephrotoxicity; Piperacillin tazobactam; vancomycin; Zosyn

Indexed keywords

CEFEPIME; CREATININE; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN; ANTIINFECTIVE AGENT; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

ACUTE KIDNEY FAILURE; ARTICLE; CREATININE BLOOD LEVEL; HUMAN; INTENSIVE CARE; LOADING DRUG DOSE; MINIMUM PLASMA CONCENTRATION; MONOTHERAPY; ADULT; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; META ANALYSIS;

ACUTE KIDNEY INJURY; ADULT; ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; HUMANS; PENICILLANIC ACID; PIPERACILLIN; VANCOMYCIN;

EID: 85006127255     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1851     Document Type: Article

References (40)

1. Ali T, Khan I, Simpson W, et al. Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J Am Soc Nephrol 2007;18(4):1292–8.
2. Bagshaw SM, Uchino S, Bellomo R, et al. Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol 2007;2(3):431–9.
3. Weyker PD, Perez XL, Liu KD. Management of acute kidney injury and acid-base balance in the septic patient. Clin Chest Med 2016;37(2):277–88.
4. Hoste EA, Kellum JA. Acute kidney injury: epidemiology and diagnostic criteria. Curr Opin Crit Care 2006;12(6):531–7.
5. Kellum JA, Lameire N, Group KAGW. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care 2013; 17(1): 204.
6. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11(2):R31.
7. van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 2013;57(2):734–44.
8. Pfizer. Zosyn (piperacillin-tazobactam) package insert. Philadelphia, PA; 2016.
9. Liu TJ, Lam JP. Piperacillin-tazobactam-induced acute interstitial nephritis with possible meropenem cross-sensitivity in a patient with osteomyelitis. Am J Health Syst Pharm 2012;69(13):1109.
10. Mannaerts L, Van der Wurff AA, Wolfhagen FH. Interstitial nephritis attributed to treatment with piperacillin-tazobactam and with ciprofloxacin. Ned Tijdschr Geneeskd 2006;150(14):804–7.
11. Pill MW, O'Neill CV, Chapman MM, Singh AK. Suspected acute interstitial nephritis induced by piperacillin-tazobactam. Pharmacotherapy 1997;17(1):166–9.
12. Peyko V, Smalley S, Cohen H. Prospective comparison of acute kidney injury during treatment with the combination of piperacillin-tazobactam and vancomycin versus the combination of cefepime or meropenem and vancomycin. J Pharm Pract 2016;29(1):1–5.
13. Sutton JD, Mynatt RP, Kaye KS, Murray KP, Rybak MJ, Pogue JM. Nephrotoxicity comparison of two commercially available generic vancomycin products. Antimicrob Agents Chemother 2015;59(9):5470–4.
14. Fodero KE, Horey AL, Krajewski MP, Ruh CA, Sellick JA Jr, Mergenhagen KA. Impact of an antimicrobial stewardship program on patient safety in veterans prescribed vancomycin. Clin Ther 2016;38(3):494–502.
15. Gomes DM, Smotherman C, Birch A, et al. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. Pharmacotherapy 2014;34(7):662–9.
16. Meaney CJ, Hynicka LM, Tsoukleris MG. Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors. Pharmacotherapy 2014;34(7):653–61.
17. Kim T, Kandiah S, Patel M, et al. Risk factors for kidney injury during vancomycin and piperacillin/tazobactam administration, including increased odds of injury with combination therapy. BMC Res Notes 2015;8:579.
18. Burgess LD, Drew RH. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy 2014;34(7):670–6.
19. Moenster RP, Linneman TW, Finnegan PM, Hand S, Thomas Z, McDonald JR. Acute renal failure associated with vancomycin and beta-lactams for the treatment of osteomyelitis in diabetics: piperacillin-tazobactam as compared with cefepime. Clin Microbiol Infect 2014;20(6):O384–9.
20. Hammond DA, Smith MN, Painter JT, Meena NK, Lusardi K. Comparative incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin-tazobactam or cefepime: a retrospective cohort study. Pharmacotherapy 2016;36(5):463–71.
21. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009;151(4):W65–94.
22. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in metaanalyses. Available from http://www.ohri.ca/programs/clinical_epidemiology/oxford.a. Accessed July 5, 2016.
23. Cochrane Handbook for Systematic Reviews. Identifying and measuring heterogeneity. Available from http://handbook.cochrane.org/chapter_9/9_5_2_identifying_and_measuring_heterogeneity.htm. Accessed August 15, 2016.
24. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56(2):455–63.
25. Orwin RG. A Fail-SafeN for effect size in meta-analysis. J Educ Behav Stat 1983;8(2):157–9.
26. Balasubramanian R, Bero J, Golfus G, Murphy A, Tran T. Impact of concomitant use of vancomycin and piperacillin-tazobactam on nephrotoxicity in adult inpatients in a community hospital [abstract 5-043]. In: Abstracts of the American Society of Health-System Pharmacists Midyear Meeting. Orlando, FL: American Society for Health-System Pharmacists Midyear Meeting, 2013.
27. Garst M. Does vancomycin or piperacillin/tazobactam have the greater potential for acute kidney injury [abstract 4-176]. In: Abstracts of the American Society of Health-System Pharmacists Midyear Meeting. Anaheim, CA: American Society for Health-System Pharmacists Midyear Meeting, 2014.
28. Katchan L, Seidel T, Bui J, Younus F. Does concomitant administration of piperacillin tazobactam with vancomycin really increase the incidence of acute kidney injury [abstract]. Pharmacotherapy 2015;35(11):e175–325.
29. Hellwig T, Hammerquist R, Loecker B, Shields J. Retrospective evaluation of the incidence of vancomycin and/or piperacillin-tazobactam induced acute renal failure [abstract]. Crit Care Med 2011;12:79.
30. Min E, Box K, Lane J, et al. Acute kidney injury in patients receiving concomitant vancomycin and piperacillin/tazobactam [abstract]. Crit Care Med 2011;12:200.
31. Norbury WB, Killion EA, Lee JO, Herndon DN. An increased incidence of acute kidney injury in severely injured burns patients is associated with piperacillin-tazobactam [abstract 50]. In: Abstracts of the 46th Annual Meeting of The American Burn Association. Boston, MA: The American Burn Association, 2014.
32. Agbabiaka TB, Savovic J, Ernst E. Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf 2008;31(1):21–37.
33. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965;85:295–300.
34. Karino S, Kaye KS, Navalkele B, et al. Epidemiology of acute kidney injury among patients receiving concomitant vancomycin and piperacillin-tazobactam: opportunities for antimicrobial stewardship. Antimicrob Agents Chemother 2016;60(6):3743–50.
35. Ichai C, Vinsonneau C, Souweine B, et al. Acute kidney injury in the perioperative period and in intensive care units (excluding renal replacement therapies). Anaesth Crit Care Pain Med 2016;35(2):151–65.
36. Jensen JUS, Hein L, Lundgren B, et al. Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial. BMJ Open 2012;2(2):1–8.
37. Mendez MN, Gibbs L, Jacobs RA, McCulloch CE, Winston L, Guglielmo BJ. Impact of a piperacillin-tazobactam shortage on antimicrobial prescribing and the rate of vancomycin-resistant enterococci and Clostridium difficile infections. Pharmacotherapy 2006;26(1):61–7.
38. Alston WK, Ahern JW. Increase in the rate of nosocomial Clostridium difficile-associated diarrhoea during shortages of piperacillin-tazobactam and piperacillin. J Antimicrob Chemother 2004;53(3):549–50.
39. American Society of Health-System Pharmacists. Drug Shortages. Available from http://www.ashp.org/menu/DrugShortages. Accessed August 18, 2016.
40. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat Med 2007;26(25):4544–62.